- Home
- IBRX vs AGM Comparison
IBRX vs AGM Comparison
Compare IBRX & AGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- AGM
- Stock Information
- Founded
- IBRX 2014
- AGM 1987
- Country
- IBRX United States
- AGM United States
- Employees
- IBRX N/A
- AGM N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- AGM Finance Companies
- Sector
- IBRX Health Care
- AGM Finance
- Exchange
- IBRX Nasdaq
- AGM Nasdaq
- Market Cap
- IBRX 1.9B
- AGM 2.2B
- IPO Year
- IBRX N/A
- AGM N/A
- Fundamental
- Price
- IBRX $3.42
- AGM $208.29
- Analyst Decision
- IBRX Strong Buy
- AGM Hold
- Analyst Count
- IBRX 3
- AGM 1
- Target Price
- IBRX $13.58
- AGM $205.00
- AVG Volume (30 Days)
- IBRX 6.0M
- AGM 31.3K
- Earning Date
- IBRX 03-18-2025
- AGM 02-21-2025
- Dividend Yield
- IBRX N/A
- AGM 2.69%
- EPS Growth
- IBRX N/A
- AGM 3.98
- EPS
- IBRX N/A
- AGM 16.44
- Revenue
- IBRX $7,332,000.00
- AGM $363,685,000.00
- Revenue This Year
- IBRX $2,359.81
- AGM N/A
- Revenue Next Year
- IBRX $808.10
- AGM $6.65
- P/E Ratio
- IBRX N/A
- AGM $12.66
- Revenue Growth
- IBRX 1218.71
- AGM 3.85
- 52 Week Low
- IBRX $2.28
- AGM $169.17
- 52 Week High
- IBRX $10.53
- AGM $217.60
- Technical
- Relative Strength Index (RSI)
- IBRX 52.26
- AGM 65.97
- Support Level
- IBRX $3.35
- AGM $194.45
- Resistance Level
- IBRX $4.27
- AGM $201.46
- Average True Range (ATR)
- IBRX 0.31
- AGM 3.98
- MACD
- IBRX 0.04
- AGM 0.54
- Stochastic Oscillator
- IBRX 29.17
- AGM 79.70
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About AGM Federal Agricultural Mortgage Corporation
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Rural Utilities, Renewable Energy, Funding, Investments, and Corporate. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.